68 Participants Needed

Cognitive Behavioral Therapy for Nonepileptic Seizures

AF
Overseen ByAaron Fobian, PhD
Age: < 65
Sex: Any
Trial Phase: Academic
Sponsor: University of Alabama at Birmingham
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This trial tests ReACT therapy for children aged 11-18 with PNES. The therapy aims to help them feel more in control and less worried about their symptoms, potentially reducing seizure-like episodes.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment ReACT, Retraining and Control Therapy, for nonepileptic seizures?

Research shows that cognitive behavioral therapy (CBT), which is similar to ReACT, can reduce the number of nonepileptic seizures and improve symptoms like depression and anxiety, as well as overall quality of life.12345

Is Cognitive Behavioral Therapy (CBT) safe for treating nonepileptic seizures?

Cognitive Behavioral Therapy (CBT) for nonepileptic seizures has been studied and shown to improve symptoms like depression and anxiety without significant safety concerns reported. It is generally considered safe for humans, as no major adverse effects were noted in the studies reviewed.14567

How is the treatment ReACT different from other treatments for nonepileptic seizures?

ReACT (Retraining and Control Therapy) is unique because it focuses on cognitive behavioral therapy (CBT) specifically tailored for nonepileptic seizures, aiming to reduce seizure frequency and improve psychiatric symptoms and quality of life. Unlike standard medical care or medications like antidepressants, ReACT uses structured therapy sessions to address the psychological aspects of the condition.158910

Eligibility Criteria

This trial is for young people aged 9-18 with a diagnosis of psychogenic non-epileptic seizures (PNES) confirmed by video-EEG. They must experience at least four PNES per month and have a family member willing to participate. It's not suitable for those with severe mental illness, other nonepileptic events, participation in another therapy, severe intellectual disability, or comorbid epilepsy.

Inclusion Criteria

A family member agrees to join the study with me.
I am between 9 and 18 years old.
My seizures have been diagnosed as non-epileptic by a doctor using a special video test.
See 1 more

Exclusion Criteria

I have epilepsy in addition to my primary condition.
I experience fewer than 4 psychogenic non-epileptic seizures monthly.
I experience sudden episodes not caused by epilepsy, such as those related to sleep disorders or migraines.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Baseline Assessment

Participants and their parents complete questionnaires and assessments including demographics, mood, suicidality, and PNES symptoms. Initial Cold Pressor Test (CPT) is conducted.

1 day
1 visit (in-person)

Treatment

Participants undergo 12 weekly sessions of Retraining and Control Therapy (ReACT) to address sense of control and catastrophic symptom expectations.

12 weeks
12 visits (1 in-person, 11 virtual)

Post-Treatment Assessment

Participants return for post-treatment assessments 1 week after the 8th and 12th therapy sessions to perform tasks and fill out questionnaires.

2 weeks
2 visits (in-person)

Follow-up

Participants are monitored for PNES frequency and complete long-term follow-up visits via Zoom at 6 months and 12 months after the 12th treatment session.

12 months
2 visits (virtual)

Booster Sessions (Optional)

Half of the participants receive 2 booster therapy sessions at 3 months and 9 months after the 12th treatment session.

6 months
2 visits (virtual)

Treatment Details

Interventions

  • ReACT
Trial OverviewThe study tests Retraining and Control Therapy (ReACT), which aims to improve the sense of control and reduce catastrophic symptom expectations in children with PNES through twelve sessions. The effectiveness will be measured using tasks like holding a hand in cool water and questionnaires before treatment, after certain sessions, and up to one year later.
Participant Groups
5Treatment groups
Experimental Treatment
Active Control
Group I: ReACT for PNES- No Booster therapy sessionsExperimental Treatment1 Intervention
After completing the 12 ReACT treatment sessions, half of the participants will be randomized to not receive the 2 booster therapy sessions.
Group II: CPT- Pain sensitivity lotionExperimental Treatment1 Intervention
During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectation. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
Group III: CPT- Pain relief lotionExperimental Treatment1 Intervention
During the initial visit participant will do the cold pressor test twice to assess catastrophic symptom expectations. After completing the 1st CPT, participants will be randomized to receive a pain relief lotion or pain sensitivity lotion. Participants will then repeat the CPT with the lotion applied to their hand.
Group IV: Healthy ControlActive Control1 Intervention
Healthy controls are matched to participants with PNES based on age (+ or - 1 year), gender, race and family income. Healthy controls and their parent come for 1 baseline laboratory visit and a follow up visit 13 weeks after the baseline visit. These visits will be identical to baseline and follow-up visits of children with PNES.
Group V: ReACT for PNES- Booster therapy sessionsActive Control1 Intervention
After completing the 12 therapy sessions, half of the participants will be randomized to receive 2 booster therapy sessions, 3 months and 9 months after the 12th ReACT treatment session.

ReACT is already approved in United States for the following indications:

🇺🇸
Approved in United States as ReACT for:
  • Pediatric functional seizures

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Alabama at Birmingham

Lead Sponsor

Trials
1,677
Recruited
2,458,000+

National Institute of Mental Health (NIMH)

Collaborator

Trials
3,007
Recruited
2,852,000+

Findings from Research

Cognitive behavioral therapy (CBT) has shown efficacy in treating psychogenic nonepileptic seizures (PNES), with evidence from a pilot randomized controlled trial indicating it is more effective than standard medical care.
While the antidepressant sertraline did not significantly reduce seizure frequency compared to placebo, it did lead to a notable decrease in symptoms from pre- to post-treatment, suggesting potential benefits that warrant further investigation.
Psychogenic nonepileptic seizures: a treatment review. What have we learned since the beginning of the millennium?Baslet, G.[2021]
In a study of 105 patients with psychogenic nonepileptic seizures (PNES), those who adhered to psychotherapy (attending at least 8 sessions) experienced an 84% reduction in seizure frequency compared to 61% in those who did not adhere, indicating that consistent therapy can significantly improve outcomes.
Adherence to psychotherapy was also linked to improved quality of life and reduced emergency department visits, suggesting that engaging in treatment can lead to better overall health management for individuals with PNES.
Treatment Works, So Who's Afraid of PNES?Salpekar, J.[2020]
The primary treatment goal for nonepileptic seizures (NES) is to improve quality of life by reducing seizure frequency through a combination of education, mental health support, and gradual weaning off anticonvulsants.
With appropriate diagnosis and treatment, approximately 45% of NES patients can become seizure-free, and an additional one-third may experience a reduction in seizure frequency, highlighting the effectiveness of integrated psychiatric care alongside psychotherapy.
Nonepileptic Seizures.Bowman, ES.[2020]

References

Psychogenic nonepileptic seizures: a treatment review. What have we learned since the beginning of the millennium? [2021]
Treatment Works, So Who's Afraid of PNES? [2020]
Nonepileptic Seizures. [2020]
The frequency and management of seizures during psychological treatment among patients with psychogenic nonepileptic seizures and epilepsy. [2018]
Cognitive behavioral therapy for psychogenic nonepileptic seizures. [2018]
The feasibility of a multidisciplinary group therapy clinic for the treatment of nonepileptic seizures. [2020]
Cognitive behavior therapy for comorbid dissociative seizures in patients with epilepsy. [2021]
Measuring outcome in psychogenic nonepileptic seizures: how relevant is seizure remission? [2019]
Treatment of psychogenic nonepileptic seizures: updated review and findings from a mindfulness-based intervention case series. [2018]
Psychological and behavioural treatments for adults with non-epileptic attack disorder. [2022]